Atossa Genetics Inc. (NASDAQ:ATOS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have been given a consensus recommendation of “Hold” by the five analysts that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $20.3333.

ATOS has been the subject of several recent research reports. HC Wainwright boosted their price target on Atossa Genetics to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Ascendiant Capital Markets cut their target price on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, April 10th. Rodman & Renshaw began coverage on Atossa Genetics in a report on Tuesday, July 7th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Weiss Ratings cut Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ATOS. Ameriprise Financial Inc. bought a new position in shares of Atossa Genetics in the 2nd quarter valued at $2,468,000. Renaissance Technologies LLC grew its position in Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after acquiring an additional 514,175 shares during the last quarter. Jane Street Group LLC bought a new position in Atossa Genetics in the second quarter valued at about $381,000. Qube Research & Technologies Ltd grew its position in Atossa Genetics by 357.4% in the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after acquiring an additional 325,340 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Atossa Genetics by 4.2% during the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after acquiring an additional 245,717 shares in the last quarter. 12.74% of the stock is owned by institutional investors.

Atossa Genetics Stock Performance

Shares of ATOS stock traded up $0.01 on Tuesday, hitting $2.37. The company’s stock had a trading volume of 65,741 shares, compared to its average volume of 279,830. Atossa Genetics has a fifty-two week low of $1.70 and a fifty-two week high of $19.35. The company has a market capitalization of $20.41 million, a PE ratio of -0.74 and a beta of 1.25. The stock’s 50 day moving average is $3.76 and its 200-day moving average is $5.52.

Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings data on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.12). On average, research analysts forecast that Atossa Genetics will post -4.3 earnings per share for the current year.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.